IPCA Laboratories

IPCA Laboratories Interest Expense

The Interest Expense of IPCA Laboratories (IPCALAB.NS) as of Nov 16, 2026 is 333.70 M INR. In the previous year, Interest Expense was 887.90 M INR — a change of -62.42% (lower).

Interest Expense

333.70 MINR

YoY

-62.42%

Last updated:

Interest Expense of IPCA Laboratories is 2025 333.70 M INR. Interest Expense of IPCA Laboratories was 2024 887.90 M INR. It decreases by -62.42% lower compared to the previous year.

The IPCA Laboratories Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2018
-38.00 M INR
Jan 1, 2019
-8.00 M INR
Jan 1, 2020
-3.00 M INR
Jan 1, 2021
736.00 M INR
Jan 1, 2022
530.00 M INR
Jan 1, 2023
201.00 M INR
Jan 1, 2024
887.90 M INR
Jan 1, 2025
333.70 M INR
The IPCA Laboratories Interest Expense history
YEARInterest ExpenseYoY
333.70 MINR-62.42%
887.90 MINR+341.74%
201.00 MINR-62.08%
530.00 MINR-27.99%
736.00 MINR-24,633.33%
-3.00 MINR-62.50%
-8.00 MINR-78.95%
-38.00 MINR-125.50%
149.00 MINR-132.25%
-462.00 MINR-800.00%
66.00 MINR-108.58%
-769.00 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IPCA Laboratories Stock analysis

What does IPCA Laboratories do? Ipca Laboratories Ltd. generates revenue through the manufacturing and marketing of over 350 pharmaceutical formulations and approximately 80 active pharmaceutical ingredients (APIs), including Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts, and Propranolol. The company sells its branded products such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, and Venpower in more than 100 countries globally. Its subsidiaries, Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd, and Tonira Exports Limited, support the distribution and sales of these products across international markets. The company's primary customers are healthcare providers, hospitals, and pharmacies in over 100 countries, purchasing both generic APIs and branded formulations. Manufacturing units in India produce APIs and formulations, with the firm's subsidiaries facilitating global market access. The therapeutic segments covered by its products include cardiovascular, antimalarial, and gastrointestinal treatments, among others, driven by the demand for cost-effective pharmaceutical solutions. IPCA Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IPCA Laboratories stock

Interest Expense of IPCA Laboratories is 333.70 M INR in 2025.

Interest Expense of IPCA Laboratories changed from 887.90 M INR to 333.70 M INR, representing a -62.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense IPCA Laboratories since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's IPCA Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — IPCA Laboratories

All Key Metrics — IPCA Laboratories